Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-effects Modeling

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2011 Dec 30

PMID 22205196

Citations 9

Authors

A Dubois

S Gsteiger

S Balser

E Pigeolet

J L Steimer

G Pillai

F Mentre

Affiliations

Soon will be listed here.

Abstract

Our objective was to show, using two examples, that a pharmacokinetic (PK) similarity analysis can be performed using nonlinear mixed-effects models (NLMEM). We used two studies that compared different biosimilars: a three-way crossover trial with somatropin and a parallel-group trial with epoetin-α. For both data sets, the results of NLMEM-based analysis were compared with those of noncompartmental analysis (NCA). For the latter analysis, we performed an NLMEM-based equivalence Wald test on secondary parameters of the model: the area under the curve and the maximal concentration. Somatropin PK was described by a one-compartment model and epoetin-α PK by a two-compartment model with linear and Michaelis-Menten elimination. For both studies, similarity of PK was demonstrated by means of both NCA and NLMEM, and both methods led to similar results. Therefore, for establishing similarity, PK data can be analyzed by either of the methods. NCA is an easier approach because it does not require data modeling; however, NLMEM leads to a better understanding of the underlying biological system.

Citing Articles

Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations.

Schiavo A, Fagiolino P, Vazquez M, Troconiz I, Ibarra M Eur J Drug Metab Pharmacokinet. 2024; 49(4):507-516.

PMID: 38874900 DOI: 10.1007/s13318-024-00901-8.

Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.

Guhl M, Mercier F, Hofmann C, Sharan S, Donnelly M, Feng K J Pharmacokinet Pharmacodyn. 2022; 49(5):557-577.

PMID: 36112338 PMC: 9483500. DOI: 10.1007/s10928-022-09821-z.

Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.

Saganuwan S BMC Pharmacol Toxicol. 2021; 22(1):57.

PMID: 34635182 PMC: 8507113. DOI: 10.1186/s40360-021-00521-x.

Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.

Germovsek E, Cheng M, Giragossian C MAbs. 2021; 13(1):1964935.

PMID: 34530672 PMC: 8463036. DOI: 10.1080/19420862.2021.1964935.

Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.

Kang J, Eudy-Byrne R, Mondick J, Knebel W, Jayadeva G, Liesenfeld K Br J Clin Pharmacol. 2020; 86(11):2274-2285.

PMID: 32363771 PMC: 7576631. DOI: 10.1111/bcp.14330.

References

Stanhope R, Sorgel F, Gravel P, Pannatier Schuetz Y, Zabransky M, Muenzberg M . Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis. J Clin Pharmacol. 2010; 50(11):1339-48. DOI: 10.1177/0091270009359005. View

Ramakrishnan R, Cheung W, Wacholtz M, Minton N, Jusko W . Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004; 44(9):991-1002. DOI: 10.1177/0091270004268411. View

Zhou H, Mayer P, Wajdula J, Fatenejad S . Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol. 2004; 44(11):1235-43. DOI: 10.1177/0091270004268049. View

Retout S, Comets E, Samson A, Mentre F . Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Stat Med. 2007; 26(28):5162-79. DOI: 10.1002/sim.2910. View

Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B . The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov. 2007; 6(6):437-42. DOI: 10.1038/nrd2307. View

Pillai G, Mentre F, Steimer J . Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn. 2005; 32(2):161-83. DOI: 10.1007/s10928-005-0062-y. View

Senn S . Statisticians and pharmacokineticists: what they can still learn from each other. Clin Pharmacol Ther. 2010; 88(3):328-34. DOI: 10.1038/clpt.2010.128. View

Panhard X, Mentre F . Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Stat Med. 2005; 24(10):1509-24. DOI: 10.1002/sim.2047. View

Fuhr U, Tuculanu D, Berghout A, Balser S, Schwebig A, Saenger P . Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. Eur J Endocrinol. 2010; 162(6):1051-8. DOI: 10.1530/EJE-09-1101. View

10.

Zhu M, Bifano M, Xu X, Wang Y, LaCreta F, Grasela D . Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. Antimicrob Agents Chemother. 2008; 52(8):2836-41. PMC: 2493122. DOI: 10.1128/AAC.01366-07. View

11.

Kaniwa N, Aoyagi N, Ogata H, Ishii M . Application of the NONMEM method to evaluation of the bioavailability of drug products. J Pharm Sci. 1990; 79(12):1116-20. DOI: 10.1002/jps.2600791215. View

12.

Dubois A, Gsteiger S, Pigeolet E, Mentre F . Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs. Pharm Res. 2009; 27(1):92-104. PMC: 2881952. DOI: 10.1007/s11095-009-9980-5. View

13.

Maier G, Lockwood G, Oppermann J, Wei G, Bauer P, Grasela T . Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies. Eur J Drug Metab Pharmacokinet. 2000; 24(3):249-54. DOI: 10.1007/BF03190028. View

14.

Bergstrand M, Karlsson M . Handling data below the limit of quantification in mixed effect models. AAPS J. 2009; 11(2):371-80. PMC: 2691472. DOI: 10.1208/s12248-009-9112-5. View

15.

Sorgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M . Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009; 9:10. PMC: 2695417. DOI: 10.1186/1472-6904-9-10. View

16.

Pentikis H, Henderson J, Tran N, Ludden T . Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm Res. 1996; 13(7):1116-21. DOI: 10.1023/a:1016083429903. View

17.

Fradette C, Lavigne J, Waters D, Ducharme M . The utility of the population approach applied to bioequivalence in patients: comparison of 2 formulations of cyclosporine. Ther Drug Monit. 2005; 27(5):592-600. DOI: 10.1097/01.ftd.0000174005.51383.2f. View

18.

Krzyzanski W, Wyska E . Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2007; 377(4-6):637-45. DOI: 10.1007/s00210-007-0225-z. View

19.

Woo S, Krzyzanski W, Jusko W . Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007; 34(6):849-68. DOI: 10.1007/s10928-007-9074-0. View

20.

Gibiansky L, Gibiansky E, Kakkar T, Ma P . Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008; 35(5):573-91. DOI: 10.1007/s10928-008-9102-8. View